Supplement Documents [IFRS]

Financial results for the first six months of the fiscal year 2015 (FY2015)

ending March 31, 2016.

Astellas Pharma Inc.

- Financial Results of 2Q/FY2015
  - Six months ended September 30, 2015
  - Three months ended September 30, 2015
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

[Six months ended September 30, 2015]

1. Consolidated Results (Full Basis)

billion yen

	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	594.5	687.5	93.0	15.7%	1,247.3	1,362.0	1,384.0	11.0%
Cost of sales	159.1	168.4	9.3	5.8%	333.2			
Ratio to Sales	26.8%	24.5%			26.7%			
Gross profit	435.4	519.1	83.7	19.2%	914.1			
SG&A expenses	201.8	239.7	38.0	18.8%	452.5			
Ratio to Sales	33.9%	34.9%			36.3%			
Advertising and Sales Promotion	55.0	83.3	28.3	51.4%	138.5			
Personnel expenses	85.3	91.3	6.0	7.0%	178.1			
Other	61.4	65.1	3.7	6.0%	136.0			
R&D expenses	97.0	112.0	15.0	15.5%	206.6	229.0	238.0	15.2%
Ratio to Sales	16.3%	16.3%			16.6%	16.8%	17.2%	
Amortisation of intangible assets	17.9	21.9	4.0	22.1%	38.7			
Share of profits/losses of associates and joint ventures	0.5	-0.3	-0.8	-	0.2			
Other income	4.9	0.9	-4.0	-81.7%	12.5			
Gain on sales of property, plant and equipment	1.4	0.2	-1.2	-82.5%	1.4			
Net foreign exchange gains	1.7	-	-1.7	-	-			
Other expense	20.8	13.4	-7.4	-35.6%	43.3			
Loss on sales and disposal of property, plant and equipment	0.5	0.3	-0.3	-53.2%	1.2			
Impairment losses	8.3	6.6	-1.8	-21.2%	10.3			
Restructuring costs	11.3	-	-11.3	-	11.5			
Net foreign exchange losses	-	5.9	5.9	-	3.6			
Operating profit	103.2	132.6	29.4	28.5%	185.7	238.0	229.0	23.3%
Ratio to Sales	17.4%	19.3%			14.9%	17.5%	16.5%	
Finance income	2.3	13.3	11.1	488.2%	7.1			
Gain on sales of available-for-sale financial assets	1.0	12.1	11.0	-	5.1			
Finance expense	2.8	0.6	-2.2	-79.6%	3.1			
Impairment losses for available-for-sale financial assets	2.6	0.1	-2.5	-96.0%	2.6			
Profit before tax	102.7	145.4	42.7	41.6%	189.7	239.0	242.0	27.6%
Ratio to Sales	17.3%	21.2%			15.2%	17.5%	17.5%	
Income tax expense	32.7	42.5	9.8	30.0%	53.8			
Profit for the period	70.0	102.9	32.9	47.1%	135.9	170.0	172.0	26.6%
Ratio to Sales	11.8%	15.0%			10.9%	12.5%	12.4%	
Comprehensive income	87.8	104.9	17.1	19.5%	169.5			

2. Consolidated Results (Core Basis)

billion yen

	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 (%)
Sales	594.5	687.5	93.0	15.7%	1,247.3	1,362.0	1,384.0	11.0%
Cost of sales	159.1	168.4	9.3	5.8%	333.2			
Ratio to Sales	26.8%	24.5%			26.7%			
Gross profit	435.4	519.1	83.7	19.2%	914.1			
SG&A expenses	201.8	239.7	38.0	18.8%	452.5			
Ratio to Sales	33.9%	34.9%			36.3%			
Advertising and Sales Promotion	55.0	83.3	28.3	51.4%	138.5			
Personnel expenses	85.3	91.3	6.0	7.0%	178.1			
Other	61.4	65.1	3.7	6.0%	136.0			
R&D expenses	97.0	112.0	15.0	15.5%	206.6	229.0	238.0	15.2%
Ratio to Sales	16.3%	16.3%			16.6%	16.8%	17.2%	
Amortisation of intangible assets	17.9	21.9	4.0	22.1%	38.7			
Share of profits/losses of associates and joint ventures	0.5	-0.3	-0.8	-	0.2			
Operating profit	119.2	145.2	26.0	21.8%	216.5	238.0	244.0	12.7%
Ratio to Sales	20.0%	21.1%			17.4%	17.5%	17.6%	
Finance income	1.2	1.3	0.1	5.6%	1.9			
Finance expense	0.2	0.3	0.1	81.4%	0.4			
Profit before Tax	120.2	146.2	25.9	21.6%	218.1			
Ratio to Sales	20.2%	21.3%			17.5%			
Income tax expense	39.2	42.2	3.0	7.8%	64.8			
Profit for the period	81.1	103.9	22.9	28.2%	153.2	170.0	175.0	14.2%
Ratio to Sales	13.6%	15.1%			12.3%	12.5%	12.6%	

3. Exchange Rate

yen

	FY14 APR. - SEP.Ave.	FY15 APR. - SEP.Ave.	FY14 End	FY15 2Q End	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year
USD/Yen	103	122	120	120	110	120	121
EUR/Yen	139	135	130	135	139	125	133

∗ Exchange rate fluctuations had positive impact by 36.0 billion yen on sales and positive impact by 9.6 billion yen on Core operating profit in Q2/FY2015

4. Reconciliation of Full Basis to Core Basis

Billion yen

	FY14 APR. - SEP.			FY15 APR. - SEP.		
Account item	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**594.5**	**-**	**594.5**	**687.5**	**-**	**687.5**
Cost of sales	159.1	-	159.1	168.4	-	168.4
Gross profit	**435.4**	**-**	**435.4**	**519.1**	**-**	**519.1**
SG&A expenses	201.8	-	201.8	239.7	-	239.7
R&D expenses	97.0	-	97.0	112.0	-	112.0
Amortisation of intangible assets	17.9	-	17.9	21.9	-	21.9
Share of profits/losses of associates and joint ventures	0.5	-	0.5	-0.3	-	-0.3
Other income *1	4.9	-4.9	-	0.9	-0.9	-
Other expense *1	20.8	-20.8	-	13.4	-13.4	-
Operating profit	**103.2**	**16.0**	**119.2**	**132.6**	**12.5**	**145.2**
Finance income *2	2.3	-1.0	1.2	13.3	-12.1	1.3
Finance expense *2	2.8	-2.6	0.2	0.6	-0.3	0.3
Profit before tax	**102.7**	**17.6**	**120.2**	**145.4**	**0.7**	**146.2**
Income tax expense	32.7	6.5	39.2	42.5	-0.3	42.2
Profit for the period	**70.0**	**11.1**	**81.1**	**102.9**	**1.0**	**103.9**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, loss on the restructuring, and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

5. Segment Information by Region

billion yen

		FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 (%)
Sales		594.5	687.5	93.0	15.7%	1,247.3	1,362.0	1,384.0	11.0%
	Japan	237.2	247.1	9.9	4.2%	498.7	521.7	504.4	1.2%
	Ratio to Sales	39.9%	35.9%			40.0%	38.3%	36.4%	
	Americas	168.0	232.9	64.9	38.6%	361.0	439.8	452.1	25.2%
	Ratio to Sales	28.3%	33.9%			28.9%	32.3%	32.7%	
	EMEA	156.5	162.3	5.8	3.7%	313.3	309.4	335.0	6.9%
	Ratio to Sales	26.3%	23.6%			25.1%	22.7%	24.2%	
	Asia and Oceania	32.7	45.2	12.5	38.3%	74.2	91.1	92.5	24.6%
	Ratio to Sales	5.5%	6.6%			5.9%	6.7%	6.7%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

6. Per Share Information

	FY14 APR. - SEP.	FY15 APR. - SEP.	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year
The number of shares issued (thousand)	2,259,823	2,221,823	2,259,823		
Treasury Shares (thousand)	51,959	64,020	66,681		
The number of shares issued after deducting Treasury Shares (thousand)	2,207,864	2,157,802	2,193,141		
Earnings per share (Yen)	31.61	47.30	61.50	78.08 *	79.37
Earnings per share (Yen) core base	36.61	47.76	69.37	78.08 *	80.76
Dividend per share (Yen)	14	16	30	32	32

* The initial forecasts for "Earnings per share (Yen) " and "Earnings per share (Yen) core base " reflect acquisitions of own shares carried out from May 28 to July 10, 2015.

7. Addition to Property, Plant and Equipment

Depreciation/Amortisation

billion yen

		FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	billion yen FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 (%)
Addition to Property, Plant and Equipment									
	Consolidated	10.7	18.4	7.7	71.9%	30.6	35.0	35.0	14.4%
Depreciation(PP&E)									
	Consolidated	10.8	10.2	-0.6	-5.4%	21.3	22.5	22.5	5.5%
Amortisation(Intangible Assets) *									
	Consolidated	20.6	24.8	4.2	20.6%	44.2	53.0	50.0	13.2%

* Amortisation(Intangible Assets): Including amortisation of software, etc.

8. Sales of major products

1)Sales of global products

billion yen

	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)
XTANDI	54.6	122.3	67.7	124.0%
US	33.5	74.5	41.0	122.3%
ex-US	21.1	47.9	26.7	126.6%
Japan	5.6	13.1	7.5	132.5%
Americas (ex-US)	0.9	2.3	1.3	137.7%
EMEA	14.5	31.5	17.1	118.0%
Asia and Oceania	0.1	1.0	0.9	994.9%
Eligard	9.5	8.8	-0.6	-6.5%
EMEA	9.4	8.7	-0.7	-7.4%
Asia and Oceania	0.0	0.1	0.1	552.1%
Vesicare	66.6	69.7	3.1	4.7%
Japan	11.8	13.3	1.5	12.7%
Americas	30.6	33.3	2.8	9.0%
EMEA	21.4	20.3	-1.1	-5.0%
Asia and Oceania	2.4	2.6	0.2	9.3%
Betanis/Myrbetriq/Betmiga	22.3	38.1	15.7	70.5%
Japan	6.1	9.7	3.6	59.7%
Americas	12.2	21.4	9.3	76.2%
EMEA	4.0	6.6	2.6	65.1%
Asia and Oceania	0.1	0.3	0.2	414.4%
Harnal	27.4	27.1	-0.3	-1.1%
Sales by Astellas	25.6	25.7	0.1	0.4%
Japan	7.8	6.7	-1.1	-14.4%
EMEA	9.1	8.0	-1.1	-12.0%
Asia and Oceania	8.4	10.6	2.2	25.9%
Bulk and Royalties	1.9	1.5	-0.4	-21.2%
Prograf	95.2	104.6	9.4	9.9%
Sales by Astellas	93.4	103.1	9.7	10.3%
Japan (Including Graceptor)	23.7	25.4	1.7	7.3%
Americas	16.9	18.1	1.2	7.0%
EMEA	38.4	40.1	1.8	4.6%
Advagraf	14.0	15.8	1.9	13.3%
Asia and Oceania	14.4	19.4	5.0	34.6%
Exports to third parties	1.8	1.5	-0.2	-14.1%
Funguard/Mycamine	18.5	21.1	2.6	14.1%
Japan	5.7	6.1	0.3	5.8%
Americas	5.7	6.7	1.0	18.2%
EMEA	5.1	5.6	0.5	10.1%
Asia and Oceania	2.0	2.7	0.7	36.3%
Protopic	12.1	9.2	-2.8	-23.6%
Americas	6.5	3.3	-3.2	-49.5%
EMEA	3.9	3.3	-0.6	-15.0%
Asia and Oceania	1.6	2.5	0.9	55.8%

billion yen

	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 Change (%)
XTANDI	137.2	229.4	253.3	84.6%
US	85.7	141.6	147.6	72.2%
ex-US	51.5	87.8	105.8	105.3%
Japan	14.9	23.0	28.0	88.4%
Americas (ex-US)	2.6	4.2	4.3	65.2%
EMEA	33.4	58.8	71.1	112.8%
Asia and Oceania	0.6	1.9	2.3	280.8%
Eligard	19.0	18.1	18.2	-4.3%
EMEA	18.9	17.9	18.0	-5.1%
Asia and Oceania	0.1	0.2	0.2	219.8%
Vesicare	135.2	132.9	133.4	-1.3%
Japan	25.6	26.4	27.0	5.5%
Americas	61.4	63.8	62.4	1.5%
EMEA	42.3	36.0	38.2	-9.7%
Asia and Oceania	5.3	6.3	5.6	5.1%
Betanis/Myrbetriq/Betmiga	53.1	79.3	81.9	54.0%
Japan	14.8	23.0	22.1	49.2%
Americas	27.9	40.8	44.3	59.0%
EMEA	10.3	14.8	14.6	41.7%
Asia and Oceania	0.2	0.6	0.9	420.0%
Harnal	56.0	53.7	56.0	0.0%
Sales by Astellas	51.9	49.5	52.0	0.1%
Japan	15.0	12.9	12.8	-14.4%
EMEA	18.0	14.7	16.7	-7.0%
Asia and Oceania	18.3	21.2	21.8	19.3%
Bulk and Royalties	4.1	4.2	4.0	-2.0%
Prograf	194.7	192.6	202.5	4.0%
Sales by Astellas	190.9	190.1	199.8	4.7%
Japan (Including Graceptor)	48.1	49.9	50.7	5.3%
Americas	33.0	32.4	33.3	0.7%
EMEA	77.7	68.6	77.3	-0.5%
Advagraf	28.7			
Asia and Oceania	32.0	39.2	38.5	20.6%
Exports to third parties	3.8	2.5	2.7	-30.6%
Funguard/Mycamine	38.8	40.6	42.4	9.3%
Japan	11.8	12.2	12.1	3.0%
Americas	12.4	12.3	12.9	4.7%
EMEA	10.2	9.9	11.7	14.1%
Asia and Oceania	4.4	6.2	5.6	28.2%
Protopic	21.7	13.7	14.9	-31.2%
Americas	10.3	2.6	2.9	-71.7%
EMEA	7.8	6.6	7.0	-10.3%
Asia and Oceania	3.4	4.3	4.8	39.6%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2)Sales of products in Japan

billion yen

<Global products>	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 Change (%)
XTANDI	5.6	13.1	7.5	132.5%	14.9	23.0	28.0	88.4%
Vesicare	11.8	13.3	1.5	12.7%	25.6	26.4	27.0	5.5%
Betanis	6.1	9.7	3.6	59.7%	14.8	23.0	22.1	49.2%
Harnal	7.8	6.7	-1.1	-14.4%	15.0	12.9	12.8	-14.4%
Prograf （Including Graceptor）	23.7	25.4	1.7	7.3%	48.1	49.9	50.7	5.3%
Funguard	5.7	6.1	0.3	5.8%	11.8	12.2	12.1	3.0%
<Local products in Japan>								
Micardis [Family]	47.1	48.5	1.4	3.0%	95.7	105.2	98.5	2.9%
Micombi	5.4	5.1	-0.3	-5.2%	10.7			
Micamlo	11.4	12.7	1.3	11.3%	23.8			
Celecox	19.6	23.4	3.8	19.4%	41.8	49.6	46.9	12.4%
Symbicort	14.5	17.5	3.0	21.0%	33.0	38.1	37.0	12.2%
Bonoteo	6.1	7.1	1.0	16.8%	13.0	14.4	14.5	11.5%
Geninax	4.3	4.8	0.4	10.0%	10.4	10.4	10.6	2.7%
Vaccines	12.6	14.0	1.4	10.9%	38.8	42.4	40.0	3.1%
Argamate	2.9	3.1	0.1	4.7%	5.9	6.4	6.2	3.6%
Kiklin	0.7	0.8	0.1	12.1%	1.5	2.2	1.7	12.1%
Gonax	1.6	1.9	0.3	18.3%	3.4	4.2	4.0	17.7%
Cimzia	2.4	3.2	0.8	34.8%	5.0	7.5	6.7	34.0%
Suglat	2.6	3.5	0.9	34.7%	4.1	11.0	8.3	102.6%
Lipitor*	19.3	16.3	-3.1	-15.9%	36.7	30.6	30.5	-17.0%
Myslee	9.8	9.2	-0.6	-6.1%	19.4	18.1	17.6	-9.1%
Gaster	9.5	7.7	-1.8	-18.6%	18.0	15.1	14.8	-17.8%
Seroquel	6.6	5.7	-0.9	-14.3%	12.6	10.6	10.7	-15.1%
Total Rx Sales In Japanese market	229.5	240.0	10.5	4.6%	481.7	507.0	489.8	1.7%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015. Sales in FY2014 exclude sales of Caduet.

3)Sales of products in Americas and EMEA

billion yen

	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 Change (%)
Scan* (Americas)	32.2	40.6	8.4	26.0%	66.3	74.3	77.8	17.3%
Lexiscan	32.1	40.5	8.4	26.3%	65.9			
AmBisome (Americas)	4.2	5.5	1.3	32.3%	9.0	9.7	10.4	15.7%
Tarceva	24.7	25.5	0.8	3.3%	48.9			
(US)	17.2	18.6	1.4	8.0%	33.5			
(ex-US)	7.5	6.9	-0.6	-7.6%	15.3			
Qutenza (EMEA)	0.9	1.0	0.1	16.0%	1.9			
DIFICLIR (EMEA)	1.0	1.3	0.3	35.9%	2.0			

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4)Sales in Americas and EMEA(Local currency)

Unit:M$

Americas	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 (%)
Net Sales	1,631	1,912	281	17.3%	3,284	3,665	3,739	13.9%
XTANDI	334	630	296	88.4%	803	1,215	1,256	56.4%
US	325	611	286	88.0%	779	1,180	1,220	56.6%
Americas (ex-US)	9	19	9	101.1%	24	35	36	50.2%
Tarceva	240	210	-30	-12.6%	444			
US	167	153	-14	-8.7%	305			
ex-US	73	57	-16	-21.8%	139			
VESIcare	296	273	-23	-7.8%	559	532	516	-7.7%
Myrbetriq	118	176	58	49.1%	254	340	367	44.6%
Prograf	164	149	-16	-9.5%	301	270	275	-8.4%
Scan*	313	333	21	6.6%	603	619	643	6.7%
Lexiscan	311	332	21	6.8%	599			
MYCAMINE	55	55	-0	-0.0%	112	102	107	-4.8%
AmBisome	40	45	5	11.9%	82	81	86	5.2%
CRESEMBA	-	7	7	-	-			
Protopic	63	27	-36	-57.3%	94	21	24	-74.2%

* Adenoscan + Lexiscan

Unit:M€

EMEA	FY14 APR. - SEP.	FY15 APR. - SEP.	Change	Change (%)	FY14 Full Year	Initial Forecasts FY15 Full Year	Revised Forecasts FY15 Full Year	Change from FY14 (%)
Net Sales	1,127	1,201	75	6.6%	2,258	2,475	2,528	12.0%
XTANDI	104	233	129	124.2%	241	470	537	122.8%
Eligard	68	65	-3	-4.7%	136	143	136	-0.6%
Vesicare	154	150	-4	-2.3%	305	288	288	-5.4%
BETMIGA	29	49	20	69.8%	74	119	110	48.3%
Harnal (Omnic)	79	70	-9	-11.1%	159	151	157	-1.7%
Sales by Astellas	66	59	-6	-9.5%	130	118	126	-2.7%
Capsule	33	29	-4	-11.9%	63	60	64	0.8%
OCAS	33	31	-2	-7.2%	66	58	62	-6.0%
Bulk and Royalties	13	11	-3	-18.9%	30	33	30	2.6%
Prograf	289	308	19	6.7%	588	569	603	2.7%
Sales by Astellas	276	297	21	7.6%	560	549	583	4.1%
Advagraf	100	117	17	16.6%	207			
Exports to third parties	13	11	-1	-11.6%	28	20	20	-27.0%
MYCAMINE	37	42	5	13.2%	74	80	88	19.4%
Protopic	28	24	-3	-12.6%	56	53	53	-6.1%
Qutenza	6	7	1	19.3%	13			
DIFICLIR	7	10	3	39.8%	14			

- EMEA: Europe, Middle East and Africa

9.Consolidated statements of financial position

Billion yen

	31-Mar-15	30-Sep-15	
	Amount	Amount	Change
Assets	**1,793.6**	**1,770.7**	**-22.9**
Non-current assets	**827.6**	**817.1**	**-10.5**
Property, plant and equipment	202.9	203.7	0.8
Goodwill	136.3	136.1	-0.2
Other intangible assets	295.8	285.7	-10.2
Trade and other receivables	15.6	21.0	5.4
Investments in associates and joint ventures	2.0	3.1	1.1
Deferred tax assets	51.2	60.1	8.9
Other financial assets	110.1	91.6	-18.4
Other non-current assets	13.7	15.8	2.2
Current assets	**966.0**	**953.6**	**-12.4**
Inventories	156.9	159.1	2.2
Trade and other receivables	332.9	351.2	18.3
Income tax receivable	6.9	8.9	2.0
Other financial assets	59.9	28.8	-31.1
Other current assets	12.7	17.4	4.6
Cash and cash equivalents	396.4	388.1	-8.3
Assets held for sale	0.1	-	-0.1

Billion yen

	31-Mar-15	30-Sep-15	
	Amount	Amount	Change
Equity and Liabilities	**1,793.6**	**1,770.7**	**-22.9**
Equity	**1,317.9**	**1,323.1**	**5.2**
Equity attributable to owners of the parent	**1,317.9**	**1,323.1**	**5.2**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.8	0.0
Treasury shares	-87.0	-102.0	-15.0
Retained earnings	905.1	925.2	20.1
Other components of equity	220.0	220.0	-0.0
Liabilities	**475.7**	**447.6**	**-28.1**
Non-current liabilities	**54.8**	**52.4**	**-2.4**
Trade and other payables	0.1	1.8	1.7
Deferred tax liabilities	0.0	-	-0.0
Retirement benefit liabilities	30.1	29.5	-0.6
Provisions	4.8	3.4	-1.4
Other financial liabilities	0.6	0.8	0.2
Other non-current liabilities	19.1	16.9	-2.2
Current liabilities	**420.9**	**395.2**	**-25.7**
Trade and other payables	226.6	202.0	-24.6
Income tax payable	14.1	18.5	4.3
Provisions	85.4	89.2	3.8
Other financial liabilities	1.3	1.1	-0.2
Other current liabilities	93.4	84.4	-9.0

10. Employee

Number of employees

	FY14 2Q End	FY15 2Q End	FY14 FY End
Total	17,536	17,352	17,113
Japan	7,698	7,300	7,241
Americas	2,939	2,957	2,975
EMEA	4,681	4,727	4,628
Asia and Oceania	2,218	2,368	2,269
Total Medical Representatives	6,540	6,220	6,530

- EMEA: Europe, Middle East and Africa

11. Shareholders

	FY14 2Q End	FY15 2Q End
Banks	30.5%	30.5%
Securities	3.6%	3.6%
Other companies	3.4%	3.4%
Foreign companies	52.7%	51.4%
Individuals and others	7.5%	8.2%
Treasury Stock	2.3%	2.9%

[Three months ended September 30, 2015]

1. Consolidated Results (Full Basis)

bilion yen

	FY15			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Sales	343.7	16.4%	343.8	14.9%
Cost of sales	90.1	18.6%	78.3	-5.8%
Ratio to Sales	26.2%		22.8%	
Gross profit	253.6	15.7%	265.5	22.8%
SG&A expenses	118.7	22.4%	121.1	15.5%
Ratio to Sales	34.5%		35.2%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%
Personnel expenses	45.1	6.3%	46.2	7.7%
Other	32.0	21.4%	33.2	-5.5%
R&D expenses	56.0	17.5%	56.1	13.5%
Ratio to Sales	16.3%		16.3%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-
Other income	1.3	-53.2%	0.3	-91.0%
Gain on sales of property, plant and equipment	0.1	799.6%	0.1	-92.5%
Net foreign exchange gains	0.6	-74.3%	-	-
Other expense	7.2	-60.4%	6.9	98.4%
Loss on sales and disposal of property, plant and equipment	0.1	-54.9%	0.2	-52.3%
Impairment losses	6.6	-18.7%	-	-
Restructuring costs	-	-	-	-
Net foreign exchange losses	-	-	6.5	794.3%
Operating profit	61.9	22.4%	70.7	34.4%
Ratio to Sales	18.0%		20.6%	
Finance income	6.0	230.4%	7.3	-
Gain on sales of available-for-sale financial assets	5.5	540.2%	6.6	-
Finance expense	0.3	-86.9%	0.3	-56.6%
Impairment losses for available-for-sale financial assets	0.0	-98.5%	0.1	-87.8%
Profit before tax	67.7	34.6%	77.8	48.4%
Ratio to Sales	19.7%		22.6%	
Income tax expense	23.0	59.8%	19.4	6.4%
Profit for the period	44.6	24.4%	58.3	70.9%
Ratio to Sales	13.0%		17.0%	
Comprehensive income	71.8	219.0%	33.0	-49.4%

2. Consolidated Results (Core Basis)

bilion yen

	FY15			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Sales	343.7	16.4%	343.8	14.9%
Cost of sales	90.1	18.6%	78.3	-5.8%
Ratio to Sales	26.2%		22.8%	
Gross profit	253.6	15.7%	265.5	22.8%
SG&A expenses	118.7	22.4%	121.1	15.5%
Ratio to Sales	34.5%		35.2%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%
Personnel expenses	45.1	6.3%	46.2	7.7%
Other	32.0	21.4%	33.2	-5.5%
R&D expenses	56.0	17.5%	56.1	13.5%
Ratio to Sales	16.3%		16.3%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-
Operating profit	67.8	2.8%	77.3	45.4%
Ratio to Sales	19.7%		22.5%	
Finance income	0.6	-43.2%	0.7	188.6%
Finance expense	0.1	-20.5%	0.2	257.6%
Profit before Tax	68.3	2.2%	77.9	45.8%
Ratio to Sales	19.9%		22.6%	
Income tax expense	23.3	13.8%	19.0	1.1%
Profit for the period	45.0	-3.0%	58.9	70.0%
Ratio to Sales	13.1%		17.1%	

3. Segment Information by Region

bilion yen

		FY15			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Sales		343.7	16.4%	343.8	14.9%
	Japan	125.6	11.3%	121.5	-2.3%
	Ratio to Sales	36.6%		35.3%	
	Americas	114.8	36.9%	118.1	40.3%
	Ratio to Sales	33.4%		34.4%	
	EMEA	81.7	-0.8%	80.5	8.7%
	Ratio to Sales	23.8%		23.4%	
	Asia and Oceania	21.5	34.0%	23.7	42.4%
	Ratio to Sales	6.3%		6.9%	

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

4. Addition to Property, Plant and Equipment
Depreciation/Amortisation

bilion yen

		FY15			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Addition to Property, Plant and Equipment					
	Consolidated	12.6	273.1%	5.8	-20.9%
Depreciation(PP&E)					
	Consolidated	5.0	-4.5%	5.2	-6.2%
Amortisation(Intangible Assets) *					
	Consolidated	12.4	21.1%	12.5	20.0%

* Amortisation(Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

1)Sales of global products

bilion yen

	FY15			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
XTANDI	59.1	152.8%	63.3	102.4%
US	36.2	146.7%	38.3	103.2%
ex-US	22.8	163.2%	25.0	101.1%
Japan	6.8	346.5%	6.3	53.3%
Americas (ex-US)	1.0	151.6%	1.2	127.0%
EMEA	14.6	117.3%	16.9	118.6%
Asia and Oceania	0.4	-	0.6	937.5%
Eligard	4.4	-12.3%	4.4	0.3%
EMEA	4.4	-12.9%	4.3	-0.9%
Asia and Oceania	0.0	349.7%	0.1	819.7%
Vesicare	35.4	7.1%	34.3	2.3%
Japan	6.8	29.6%	6.5	-0.9%
Americas	17.1	9.9%	16.2	8.1%
EMEA	10.2	-7.2%	10.1	-2.7%
Asia and Oceania	1.2	7.6%	1.4	10.8%
Betanis/Myrbetriq/BETMIGA	18.1	69.1%	20.0	71.7%
Japan	4.9	81.0%	4.9	42.9%
Americas	9.8	59.7%	11.6	93.2%
EMEA	3.3	79.7%	3.3	52.7%
Asia and Oceania	0.1	447.7%	0.2	396.9%
Harnal	14.2	3.4%	12.9	-5.6%
Sales by Astellas	13.3	6.2%	12.4	-5.2%
Japan	3.4	-11.6%	3.3	-17.1%
EMEA	4.7	3.7%	3.3	-27.6%
Asia and Oceania	5.0	25.5%	5.6	26.3%
Bulk and Royalties	0.9	-25.4%	0.5	-13.1%
Prograf	50.4	7.1%	54.2	12.6%
Sales by Astellas	49.9	8.0%	53.2	12.6%
Japan (Including Graceptor)	12.7	11.0%	12.7	3.7%
Americas	8.4	-4.5%	9.7	19.4%
EMEA	19.6	5.2%	20.5	4.0%
Advagraf	7.5	13.8%	8.3	12.9%
Asia and Oceania	9.2	25.7%	10.3	43.7%
Exports to third parties	0.5	-41.3%	1.0	13.1%
Funguard/MYCAMINE	10.3	16.3%	10.8	12.0%
Japan	2.9	16.5%	3.1	-2.5%
Americas	3.3	15.5%	3.4	20.9%
EMEA	2.8	6.5%	2.8	14.0%
Asia and Oceania	1.3	49.2%	1.4	26.5%
Protopic	4.7	-22.5%	4.5	-24.6%
Americas	1.5	-51.7%	1.8	-47.5%
EMEA	1.8	-13.4%	1.5	-17.0%
Asia and Oceania	1.3	66.7%	1.3	46.1%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2)Sales of products in Japan

bilion yen

	FY15			
	APR.-JUN.	Change	JUL.-SEP.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	6.8	346.5%	6.3	53.3%
Vesicare	6.8	29.6%	6.5	-0.9%
Betanis	4.9	81.0%	4.9	42.9%
Harnal	3.4	-11.6%	3.3	-17.1%
Prograf （Including Graceptor）	12.7	11.0%	12.7	3.7%
Funguard	2.9	16.5%	3.1	-2.5%
<Local products in Japan>				
Micardis [Family]	24.8	6.3%	23.7	-0.3%
Micombi	2.7	-3.0%	2.5	-7.5%
Micamlo	6.5	14.5%	6.2	8.1%
Celecox	11.8	41.4%	11.6	3.0%
Symbicort	9.0	44.2%	8.5	3.5%
Bonoteo	3.7	39.8%	3.4	-0.9%
Geninax	2.8	20.9%	2.0	-2.5%
Vaccines	6.6	24.6%	7.4	1.1%
Argamate	1.5	6.5%	1.5	2.9%
Kiklin	0.4	23.2%	0.4	3.0%
Gonax	0.9	26.1%	1.0	11.6%
Cimzia	1.6	40.1%	1.6	29.9%
Suglat	2.0	-18.2%	1.4	-
Lipitor*	8.3	-13.1%	7.9	-18.6%
Myslee	4.7	-3.6%	4.6	-8.5%
Gaster	3.9	-17.4%	3.8	-19.8%
Seroquel	3.0	-13.4%	2.7	-15.3%
Total Rx Sales In Japanese market	122.2	12.1%	117.8	-2.3%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015.

3)Sales of products in Americas and EMEA

bilion yen

		FY15			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
Scan*	(Americas)	20.8	25.1%	19.8	27.1%
Lexiscan		20.8	26.2%	19.7	26.4%
AmBisome	(Americas)	2.8	47.7%	2.7	19.5%
Tarceva		13.1	-3.2%	12.4	11.1%
	(US)	9.7	0.5%	8.9	17.4%
	(ex-US)	3.4	-12.3%	3.5	-2.4%
Qutenza	(EMEA)	0.5	16.3%	0.5	15.6%
DIFICLIR	(EMEA)	0.6	34.7%	0.7	37.1%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4)Sales in Americas and EMEA(Local currency)

Unit:M$

Americas	FY15 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Net Sales	946	15.2%	966	19.3%
XTANDI	307	107.8%	323	73.1%
US	298	107.6%	313	72.5%
Americas (ex-US)	9	111.8%	10	92.7%
Tarceva	108	-18.5%	101	-5.4%
US	80	-15.4%	73	0.0%
ex-US	28	-26.1%	28	-16.9%
VESIcare	141	-7.5%	133	-8.0%
Myrbetriq	81	34.4%	95	64.4%
Prograf	69	-19.6%	80	1.6%
Scan*	171	5.3%	162	8.1%
Lexiscan	171	6.2%	161	7.5%
MYCAMINE	27	-2.8%	28	2.8%
AmBisome	23	24.3%	22	1.4%
CRESEMBA	2	-	5	-
Protopic	12	-59.4%	14	-55.4%

* Adenoscan + Lexiscan

Unit:M€

EMEA	FY15 APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Net Sales	609	3.5%	592	10.0%
XTANDI	109	126.9%	125	121.9%
Eligard	33	-9.1%	32	0.3%
Vesicare	76	-3.1%	75	-1.4%
BETMIGA	25	87.7%	25	54.9%
Harnal (Omnic)	42	1.8%	28	-25.2%
Sales by Astellas	35	8.2%	24	-26.9%
Capsule	18	14.3%	11	-37.0%
OCAS	17	2.4%	14	-16.7%
Bulk and Royalties	7	-22.1%	4	-13.0%
Prograf	150	7.6%	158	5.9%
Sales by Astellas	146	9.8%	151	5.5%
Advagraf	56	18.8%	61	14.6%
Exports to third parties	4	-38.8%	7	15.0%
MYCAMINE	21	11.2%	20	15.4%
Protopic	14	-9.5%	11	-16.2%
Qutenza	4	21.5%	3	16.9%
DIFICLIR	5	40.7%	5	39.0%

- EMEA: Europe, Middle East and Africa

R&D Pipeline (As of October 2015)

Changed underlined items from the previous announcement on July 31st, 2015

1. Global Development

(1) Filed

*Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor*	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Overactive bladder in pediatric patients of 5-18 years	Europe Filed (Sept. 2015)	Oral	In-house	New indication (pediatric)

(2) Phase-lll / Phase-ll (1/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Non-metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III	Oral	Medivation	New indication
		Breast cancer	US/Europe Phase-II			New indication
		Hepatocellular carcinoma	US/Europe Phase-II			New indication
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			

(2) Phase-Ⅲ / Phase-Ⅱ (2/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	US/Europe/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Merck	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan/Asia Phase-III US/Europe Phase-II	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	
ASP2215 gilteritinib	FLT3/AXL inhibitor	Acute myeloid leukemia	US/Europe/Japan/Asia Phase-III	Oral	In-house	
		Non-small cell lung cancer	US/Japan/Asia Phase-I			
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	US/Europe/Japan/Asia Phase-III	Oral	In-house	
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	

(2) Phase-lll / Phase-ll (3/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			
ASP3662	11beta-HSD1 inhibitor	Painful diabetic peripheral neuropathy	US Phase-II	Oral	In-house	
		Alzheimer's disease	US Phase-I			
CK-2127107	Fast skeletal tropoinin activator	Spinal muscular atrophy	US Phase-II	Oral	Cytokinetics	
		Chronic obstructive pulmonary disease	US Phase-II			
ASP7962	TrkA inhibitior	Osteoarthritis	Europe Phase-II	Oral	In-house	
AGS-16C3F	ADC targeting ENPP3	Renal cell carcinoma (ADC technology)	US/Europe Phase-II	Injection	In-house (ADC technology in-licensed from Seattle Genetics)	

2. Local Development: Japan

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Filed (Mar. 2015)	Oral	Amgen	New indication
		Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Filed (Sept. 2015)	Oral		New formulation
AMG 145 evolocumab	Anti-PCSK-9 monoclonal antibody	Hypercholesterolemia	Japan Filed (Mar. 2015)	Injection	Amgen (co-development with Amgen Astellas)	

(2) Phase-III / Phase-II

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
FK949E quetiapine	Serotonin / dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome with constipation	Japan Phase-III	Oral	Ironwood	
		Chronic constipation	Japan Phase-II			
ipragliflozin/ sitagliptin	Fixed dose combination of ipragliflozin and sitagliptin	Type 2 diabetes mellitus	Japan Phase-III	Oral	In-house (co-development with MSD and Kotobuki)	
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes mellitus	Japan Phase-II	Oral	In-house (co-development with Kotobuki)	New indication

3. Local Development: Europe

(1) Approved

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
NGX-4010 capsaicin	Qutenza (Aug. 2015)	TRPV1 agonist	Peripheral neuropathic pain in adults*	Europe	Patch	HealthCare Royalty Partners	New indication

*Previous indication was peripheral neuropathic pain in non-diabetic adults. The label was extended to include adult diabetic patients with peripheral neuropathic pain.

4. Local Development: US

(1) Phase-lll / Phase-ll

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
isavuconazonium sulfate	Azole antifungal	Candidemia / Invasive candidiasis	US Phase-III	Injection Oral	Basilea	New indication

5. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Licensor
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP5878	Cancer	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP2205	Stress urinary incontinence	Oral	In-house
ASP5094	Rheumatoid arthritis	Injection	In-house
ASP6858	Chronic kidney disease	Oral	In-house
AMG 103 blinatumomab	Acute lymphoblastic leukemia	Injection	Amgen (co-development with Amgen Astellas)
ASP4132	Cancer	Oral	In-house
ASP4345	Cognitive impairment associated with schizophrenia	Oral	In-house
ASP6282	Underactive bladder	Oral	In-house
ASP4070 (JRC2-LAMP-vax)	Pollinosis caused by Japanese red cedar	Injection	Immunomic Therapeutics
ASP0819	Fibromyalgia	Oral	In-house
ASP8062	Fibromyalgia	Oral	In-house

6. Project Discontinued

(1) Phase-lll / Phase-ll

Code No. Generic Name	Target Disease	Area / Phase	Reason
ASP8477	Neuropathic pain	Europe Phase-II	Development was discontinued because the Phase-II study did not demonstrate the expected efficacy.

(2) Phase-I

Code No. Generic Name	Target Disease
ASP5633	Stress urinary incontinence

7. Other items changed from the previous financial announcement on July 31st, 2015

-Removed the description of Cimzia (certolizumab pegol), for which new indication was approved in Japan in May 2015.

-Removed the description of Irribow (ramosetron), for which new indication was approved in Japan in May 2015.